Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 337-342

  Derikx, J P M ^a   Blijlevens, N M A ^b   Donnelly, J P ^b   Fujii, H ^c,e   Kanda, T ^d   van Bijnen, A A ^b   Heineman, E ^a   Buurman, W A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NIIGATA UNIVERSITY   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

^e SHINSHU UNIVERSITY   (Japan)

Author keywords

Enterocyte mass; Enterocyte turnover; Mucositis; Myeloablative therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BILE ACID BINDING PROTEIN; BINDING PROTEIN; CITRULLINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FATTY ACID BINDING PROTEIN; IDARUBICIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FATTY ACID BLOOD LEVEL; FEMALE; FEVER; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; INTESTINE BRUSH BORDER; INTESTINE CELL; MALE; MORBIDITY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION DOSE FRACTIONATION; WHOLE BODY RADIATION;

EID: 60549105012     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn579     Document Type: Article

References (25)

1. Peterson DE, Cariello A. Mucosal damage: A major risk factor for severe complications after cytotoxic therapy. Semin Oncol 2004; 31: 35-44.
2. Niscola P, Romani C, Cupelli L et al. Mucositis in patients with hematologic malignancies: An overview. Haematologica 2007; 92: 222-231.
3. Blijlevens NM. Implications of treatment-induced mucosal barrier injury. Curr Opin Oncol 2005; 17: 605-610.
4. Keefe DM, Brealey J, Goland GJ et al. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47: 632-637.
5. Verburg M, Renes IB, Meijer HP et al. Selective sparing of goblet cells and paneth cells in the intestine of methotrexate-treated rats. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1037-G1047.
6. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-284.
7. Blijlevens NM, Lutgens LC, Schattenberg AV et al. Citrulline: A potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004; 34: 193-196.
8. Lutgens LC, Blijlevens NM, Deutz NE et al. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 2005; 103: 191-199.
9. Crenn P, Coudray-Lucas C, Thuillier F et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000; 119: 1496-1505.
10. van de Poll MC, Ligthart-Melis GC, Boelens PG et al. Intestinal and hepatic metabolism of glutamine and citrulline in humans. J Physiol 2007; 581: 819-827.
11. Lieberman JM, Sacchettini J, Marks C et al. Human intestinal fatty acid binding protein: Report of an assay with studies in normal volunteers and intestinal ischemia. Surgery 1997; 121: 335-342.
12. Kanda T, Fujii H, Tani T et al. Intestinal fatty acid-binding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology 1996; 110: 339-343.
13. Derikx JP, Evennett NJ, Degraeuwe PL et al. Urine based detection of intestinal mucosal cell damage in neonates with suspected necrotising enterocolitis. Gut 2007; 56: 1473-1475.
14. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta 2005; 352: 15-35.
15. Fujita M, Fujii H, Kanda T et al. Molecular cloning, expression, and characterization of a human intestinal 15-kDa protein. Eur J Biochem 1995; 233: 406-413.
16. Watanabe K, Hoshi N, Tsuura Y et al. Immunohistochemical distribution of intestinal 15 kDa protein in human tissues. Arch Histol Cytol 1995; 58: 303-306.
17. Verburg M, Renes IB, Van Nispen DJ et al. Specific responses in rat small intestinal epithelial mRNA expression and protein levels during chemotherapeutic damage and regeneration. J Histochem Cytochem 2002; 50: 1525-1536.
18. Blijlevens NM, Donnelly JP, Naber AH et al. A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Support Care Cancer 2005; 13: 790-796.
19. Schaap N, Schattenberg A, Bar B et al. Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen. Br J Haematol 1997; 98: 750-759.
20. Derikx JP, Poeze M, van Bijnen AA et al. Evidence for intestinal and liver epithelial cell injury in the early phase of sepsis. Shock 2007; 28: 544-548.
21. Bullen TF, Forrest S, Campbell F et al. Characterization of epithelial cell shedding from human small intestine. Lab Invest 2006; 86: 1052-1063.
22. Vigneulle RM, Rao S, Fasano A et al. Structural and functional alterations of the gastrointestinal tract following radiation-induced injury in the rhesus monkey. Dig Dis Sci 2002; 47: 1480-1491.
23. Fanning SR, Rybicki L, Kalaycio M et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 2006; 135: 374-381.
24. Blijlevens NM, Sonis ST. Palifermin (recombinant keratinocyte growth factor-1): A pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18: 817-826.
25. Keefe DM. Intestinal mucositis: Mechanisms and management. Curr Opin Oncol 2007; 19: 323-327.